Alivus Life Sciences Ltd.

The Revenue for the quarter ended  March 2023 of Rs. 6213.20 millions grew by 20.87 % from Rs. 5140.57 millions.Net Profit recorded in the quarter ended March 2023 rise to 47.99% to Rs. 1463.57  millions  compared to R. 988.97 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 2092.66 millions from 1473.06 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202303	202203	% Var	202303	202203	% Var	202303	202203	% Var
Sales	6213.20	5140.57	20.87	21612.20	21232.14	1.79	21612.20	21232.14	1.79
Other Income	28.36	50.95	-44.34	289.57	147.04	96.93	289.57	147.04	96.93
PBIDT	2092.66	1473.06	42.06	6712.50	6307.64	6.42	6712.50	6307.64	6.42
Interest	1.19	1.25	-4.80	5.47	279.62	-98.04	5.47	279.62	-98.04
PBDT	2091.47	1471.81	42.10	6707.03	6028.02	11.26	6707.03	6028.02	11.26
Depreciation	115.17	95.54	20.55	420.94	378.77	11.13	420.94	378.77	11.13
PBT	1976.30	1376.27	43.60	6286.09	5649.25	11.27	6286.09	5649.25	11.27
TAX	512.73	387.30	32.39	1616.48	1462.01	10.57	1616.48	1462.01	10.57
Deferred Tax	39.62	18.25	117.10	110.37	85.74	28.73	110.37	85.74	28.73
PAT	1463.57	988.97	47.99	4669.61	4187.24	11.52	4669.61	4187.24	11.52
Equity	245.05	245.05	0.00	245.05	245.05	0.00	245.05	245.05	0.00
PBIDTM(%)	33.68	28.66	17.54	31.06	29.71	4.55	31.06	29.71	4.55